$BLLN

Sakakibara Shan Riku sold $1.0M of BLLN

Sakakibara Shan Riku (Chief Product Officer) sold 8,000 shares of BillionToOne, Inc. (BLLN) at $125.00 ($1.00M total) across 5 trades on 2026-07-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sakakibara Shan Riku
Published Jul 13, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
high confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The newest disclosed fact is the CPO’s $1.0M open-market sale under a pre-arranged 10b5-1 plan; it does not include any new business, clinical, or regulatory development.

02

Market read

Traders may treat this as low-signal insider activity rather than a fundamental catalyst, but it can marginally influence short-term sentiment.

03

What to watch

The article does not disclose whether other insiders sold/bought around the same time, nor does it provide context on option exercises, tax-related liquidity needs, or planned future tranches.

Relevance 5/10Novelty 3/10Timing: filed 2026-07-13, transaction dated 2026-07-09

Background

This is an SEC Form 4 insider transaction disclosure for BillionToOne, Inc. (BLLN).

Company-level read

Ticker impact

$BLLNNeutralHigh confidence
Context

BillionToOne insider Form 4 shows CPO Sakakibara Shan Riku sold 8,000 shares at $125 on a 10b5-1 plan, totaling $1.0M.

Expected impact

Low likelihood of a sustained price move solely from this transaction; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

Form 4 details a pre-arranged 10b5-1 plan and a single-day sale at a fixed price, which typically reduces interpretive value versus discretionary selling.

Market effects

Minimal, as this is company-specific insider trading with no disclosed operational or regulatory change.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider sales can coincide with internal expectations of limited upside, so traders may still watch for follow-on selling or weak demand signals.

Key entities

  • BillionToOne, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Sakakibara Shan Riku

    Chief Product Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BLLNLow

BillionToOne's Northstar Response Shows High Concordance In Advanced Cancer Study

BillionToOne (BLLN) published a study showing its Northstar Response liquid biopsy assay had high concordance with a commercial ctDNA assay in advanced cancer patients. The study of 61 patients found 94% agreement in tumor burden change direction, with Northstar Response aligning with clinical ground truth in discordant cases. The assay detects disease progression even when tumors evolve post-biopsy. BLLN shares closed at $22.71, down 0.79%.

$BLLNMedAI 8/10

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

BillionToOne (BLLN) announced a peer-reviewed study showing its Northstar Response® liquid biopsy assay performed on par or better than a tumor-informed assay in tracking cancer treatment. The study, published in The Journal of Liquid Biopsy, evaluated 169 samples from 61 patients, finding close alignment in results (R² = 0.97) and agreement in 94% of cases. Northstar Response detected disease progression in cases where the tumor-informed assay did not, highlighting its tumor-agnostic benefits.

$BLLNMedAI 8/10

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)

BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.

$BLLNMed

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

BillionToOne, Inc. (BLLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance MENLO PARK, CA, August 5, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to al

$BLLNMedAI 8/10

Billiontoone (BLLN) – Research Analysts’ Recent Ratings Updates

BillionToOne (NASDAQ: BLLN) saw multiple analyst rating and target changes. Weiss Ratings upgraded BLLN to “sell (d+)” (from “sell (d)”) on 5/15 and reaffirmed “sell (d)” on 5/1. Guggenheim raised its target to $120 (from $100) and kept a “buy” on 5/13. JPMorgan lifted its target to $125 and maintained “overweight” on 5/7. BTIG cut its target to $130 (from $140) while keeping “buy” on 5/7.